Publications by authors named "Germana Tognon"

Claim this Profile
L
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.
Alessio Carbone, Elena Biagioli, Vanda Salutari, Domenica Lorusso, Nicoletta Provinciali, Germana Tognon

Tumori· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Significance of Soluble L1CAM Serum Levels in Patients with High-Risk Endometrial Cancer.
Antonella Ravaggi, Cosetta Bergamaschi, Laura Zanotti, Elisa Gozzini, Marina Momi, Germana Tognon

Biomedicines· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.
Yann Christinat, Intidhar Labidi-Galy, Liza Ho, Sophie Clément, Catherine Genestie, Germana Tognon

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.
François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Germana Tognon

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
Eliana Bignotti, Vittorio Simeon, Laura Ardighieri, Elisabetta Kuhn, Sergio Marchini, Germana Tognon

Int J Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
Antonio González-Martín, María Jesús Rubio, Florian Heitz, René Depont Christensen, Nicoletta Colombo, Germana Tognon

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial.
Stefano Indraccolo, Simona Signoriello, Ilaria Piga, Giovanni Esposito, Federica Ferrarini, Germana Tognon

Int J Biol Markers· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Germana Tognon

Lancet Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.
Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, Giorgio Valabrega, Nicoletta Colombo, Germana Tognon

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
Yann Christinat, Liza Ho, Sophie Clément, Catherine Genestie, Jalid Sehouli, Germana Tognon

JCO Precis Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.
Luca Forlani, Loris De Cecco, Vittorio Simeon, Biagio Paolini, Marina Bagnoli, Germana Tognon

J Exp Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma.
Antonella Ravaggi, Davide Capoferri, Laura Ardighieri, Iacopo Ghini, Federico Ferrari, Germana Tognon

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
Chiara Romani, Davide Capoferri, Casper Reijnen, Silvia Lonardi, Antonella Ravaggi, Germana Tognon

Int J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Nicoletta Colombo, Federica Tomao, Pierluigi Benedetti Panici, Maria Ornella Nicoletto, Germana Tognon

Gynecol Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
Laura Ardighieri, Francesco Missale, Mattia Bugatti, Luisa Benerini Gatta, Irene Pezzali, Germana Tognon

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Germana Tognon

Int J Gynecol Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.
Daniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, Rossella De Cecio, Laura Arenare, Germana Tognon

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
Paola Todeschini, Elisa Salviato, Chiara Romani, Vittoria Raimondi, Francesco Ciccarese, Germana Tognon

Cancers (Basel)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Germana Tognon

Int J Gynecol Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients.
Eliana Bignotti, Laura Zanotti, Paola Todeschini, Valentina Zizioli, Chiara Romani, Germana Tognon

Front Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Giuseppe Benvenuto, Paola Todeschini, Lara Paracchini, Enrica Calura, Robert Fruscio, Germana Tognon

Int J Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Domenica Lorusso, Alessandra Bologna, Sabrina Chiara Cecere, Elisabetta De Matteis, Giusy Scandurra, Germana Tognon

Support Care Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study.
Enrica Calura, Matteo Ciciani, Andrea Sambugaro, Lara Paracchini, Giuseppe Benvenuto, Germana Tognon

Cells· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Renata A Tassi, Angela Gambino, Laura Ardighieri, Eliana Bignotti, Paola Todeschini, Germana Tognon

Br J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
Nicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, Simona Frezzini, Giovanni Scambia, Germana Tognon

Br J Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis